Citi initiated coverage on Keryx Biopharmaceuticals (NASDAQ: KERX) with a Sell rating and a price target of $1.50.

For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.

Shares of Keryx Biopharmaceuticals closed at $6.03 yesterday.